Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

BMC Pediatrics

Volumn 10, Issue , 2010, Pages

  Itzler, Robbin ^a   Koch, Gary ^b   Matson, David O ^c   Gothefors, Leif ^d   Van Damme, Pierre ^d,e   DiNubile, Mark J ^a   Heaton, Penny M ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f NOVARTIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; LIVE VACCINE;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HEALTH CARE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INFANT; INTERNAL CONSISTENCY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PARENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; SEROTYPE; SYMPTOM; TELEPHONE; TREATMENT OUTCOME; VACCINATION; VIRAL GASTROENTERITIS; VIRUS STRAIN; CLASSIFICATION; EMERGENCY HEALTH SERVICE; EVALUATION; GASTROENTERITIS; GENETIC REASSORTMENT; IMMUNIZATION; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL; ROTAVIRUS INFECTION; SEROTYPING; STATISTICS; UTILIZATION REVIEW; VIROLOGY;

CLINICAL TRIALS, PHASE III AS TOPIC; EMERGENCY SERVICE, HOSPITAL; GASTROENTERITIS; HOSPITALIZATION; HUMANS; IMMUNIZATION SCHEDULE; INFANT; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEROTYPING; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 77954859695     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-10-42     Document Type: Article

References (28)

1. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 50(RR-12):1-16.
2. Giaquinto C, Van Damme P, Huet F, Gothefors L, Maxwell M, Todd P, da Dalt L. Clinical consequences of rotavirus gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007, 195:S26-S35. 10.1086/516717, 17387649.
3. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
4. Glass RI, Lew JF, Gangarosa RE, LeBaron CW, Ho MS. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatrics 1991, 118:S27-S33.
5. American Academy of Pediatrics: Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis Practice parameter: the management of acute gastroenteritis in young children. Pediatr 1996, 97:424-436. American Academy of Pediatrics: Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis.
6. Ozuah PO, Avner JR, Stein REK. Oral rehydration, emergency physicians, and practice patterns: a national survey. Pediatr 2002, 109:259-261.
7. LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM. Annual rotavirus epidemic patterns in North America: results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA 1990, 264:983-8. 10.1001/jama.264.8.983, 2376890.
8. Turcios RM, Curns AT, Holman RC, Pandya-Smith I, LaMonte A, Bresee JS, Glass RI. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Ped Infect Dis J 2006, 25:451-4.
9. Centers for Disease Control Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory committee on Immunization Practices (ACIP). MMWR 2009, 58:RR2. Centers for Disease Control.
10. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton P. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33. 10.1056/NEJMoa052664, 16394299.
11. Ruiz-Palacios GM, Perez-Schael I, Velazquez RF, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22. 10.1056/NEJMoa052434, 16394298.
12. Vesikari T, Clark HF, Offitt PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829. 10.1016/j.vaccine.2006.03.025, 16621194.
13. Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatr 2007, 119:11-18.
14. Parashar UD, Glass R. Rotavirus vaccines - early success, remaining questions. N Engl J Med 2009, 360:1063-1065. 10.1056/NEJMp0810154, 19279338.
15. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, Parashar UD. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatr 2009, 124:465-471.
16. Clark HF, Lawley D, Mallette L, DiNubile M. Decline in cases of rotavirus gastroenteritis presenting to Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009, 16:382-386. 10.1128/CVI.00382-08, 2650872, 19158283.
17. Daskalaki I, Wood SJ, Inumerable YM, Long SS. Epidemiology of rotavirus-associated hospitalizations pre- and post-implementation of immunization: North Philadelphia, 2000-2008. Infectious Disease Society of America Conference; 25-28 October, 2008; Washington D.C
18. Mast T, Wang F, Goli V, Loughlin J, Bulotsky M, Seeger J. Post-licensure effectiveness of RotaTeq in preventing gastroenteritis. Infectious Disease Society Conference; 25-28 October 2008, Washington, D.C
19. Patel JA, Loeffelholz M. Reduction of severe rotavirus gastroenteritis following the routine use of live, oral, pentavalent rotavirus vaccine. Infectious Disease Society of America Conference, 25-28 October 2008, Washington, D.C
20. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007, 11(Suppl 2):S29-35. 10.1016/S1201-9712(07)60019-8, 18162243.
21. Sloan FA. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge University Press 1995,
22. Mato SP, Perrin K, Scardino D, Begue RE. Evaluation of rotavirus vaccine effectiveness in a pediatric group practice. Am J of Epidemiol 2002, 156:1049-55.
23. DiStefano DJ, Kraiouchkine N, Mallette L, Maliga M, Kulnis G, Keller PM, Clark HF, Shaw AR. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol 2005, 43:5876-5880. 10.1128/JCM.43.12.5876-5880.2005, 1317171, 16333070.
24. Zeger SL, Liang K-Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988, 44:1049-1060. 10.2307/2531734, 3233245.
25. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS® system. 2000, North Carolina: SAS Institute, Inc, Stokes ME, Davis CS, Koch GG, 2.
26. Jovanovic BD, Zalenski RJ. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med 1997, 30:301-306. 10.1016/S0196-0644(97)70165-3, 9287891.
27. Ciarlet M, Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq®. Vaccine 2009, 27S:G72-G81.
28. Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ. Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants. Ped Inf Dis J 2007, 26:1099-1104.